Beta Testing of a New Assessment in Huntington's Disease (HD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.

Repair-HD is an EU FP7 consortium that aims to establish all the preclinical requirements for transplantation of stem cell-derived neurons in HD in order to replace those lost to the disease process. These requirements include the generation of new clinical assessments for detailed monitoring of patients with HD who have undergone cell replacement therapy.

This protocol describes the beta testing of a new clinical assessment battery: Core Assessment Protocol for Intrastriatal Transplantation in HD version 2 (CAPIT-HD beta / CAPIT-HD2). CAPIT-HD beta represents a substantial revision of a previous CAPIT-HD battery published over 20 years ago, which is in need of updating in order to accommodate knowledge from clinical transplant studies over this time and to take advantage of technological advances in patient assessment.

HD is a complex disorder in which there is relentless deterioration of motor, cognitive and behavioural functions, usually from mid-life onwards. The original CAPIT battery aimed to capture elements of change in all three domains, but was based predominantly on subjective semi-quantitative assessment tools that have poor inter-rater reliability. Moreover, a number of deficits, such as impairments in social cognition, were not recognised when the original CAPIT-HD battery was constructed, so we have developed novel assessments of these deficits, some of which are included in CAPIT-HD beta. The beta testing will take place in established HD clinical centres in Cardiff, Manchester, Paris, and Munster by teams of researchers who are experienced in leading clinic research in HD. Patients with early to moderate HD will be assessed at baseline, and at one and twelve months later, to assess the reliability and sensitivity of the CAPIT-HD beta battery. Arrangements for data storage and analysis are in place.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long Term Follow-up Grafted Huntington's Disease Patients

NCT06194006

Huntington Disease

NOT_YET_RECRUITING NA

Deep Brain Stimulation Treatment for Chorea in Huntington's Disease

NCT04244513

Huntington Disease Deep Brain Stimulation

UNKNOWN NA

Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)

NCT02535884

Huntington Disease

COMPLETED NA

MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease

NCT00190450

Huntington Disease

COMPLETED PHASE2

Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial

NCT00518791

Parkinson's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HD patients

Group Type EXPERIMENTAL

CAPIT-HD beta

Intervention Type OTHER

New assessment protocol for assessment of complex therapies in Huntington's disease for both groups

Controls

Group Type EXPERIMENTAL

CAPIT-HD beta

Intervention Type OTHER

New assessment protocol for assessment of complex therapies in Huntington's disease for both groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAPIT-HD beta

New assessment protocol for assessment of complex therapies in Huntington's disease for both groups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be confirmed to carry the HD gene through genetic testing (CAG ≥ 36)
* Must be 18 years or above
* Stage I or II disease (TFC staging)

Exclusion Criteria

* The inability to approve consent
* Any comorbid condition that has the potential to confound the results of the study

* The inability to approve consent
* Any comorbid condition that has the potential to confound the results of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes